Michael Lowe
Overview
Dr. Lowe received his MD and graduated cum laude from Georgetown University School of Medicine. He served as administrative chief resident during the final year of his general surgery residency at the Emory Department of Surgery. He joined the Emory faculty after completing a fellowship in complex general surgical oncology at Memorial Sloan Kettering Cancer Center. Dr. Lowe received several awards during his training years, including the Young Investigator Award of the American Society of Transplant Surgeons in 2011 and 2012.
His clinical practice and research interests focus on cutaneous malignancies, particularly melanoma and Merkel cell carcinoma, and he is known for building a cutaneous malignancy program at Emory Saint Joseph's Hospital. Watch Dr. Lowe discuss aspects of treating melanoma in these educational videos produced by the Winship Cancer Institute: treating a recurrence of melanoma, using surgery to treat melanoma, and the role of the sentinel lymph node in melanoma.
In 2018, Dr. Lowe received the Society of Surgical Oncology's (SSO) Young Investigator Award for his study, "Evaluation of FcyRIIB as a Novel T cell Inhibitor in Cutaneous Melanoma." The study is investigating new pathways to enhance the immune system's response to melanoma, defining the role of the Fc receptor FcyRIIB in promoting exhaustion in T cell responses to tumor growth, and examining the benefits of blocking FcyRIIB's ability to alter T cell responses.
Academic Appointment
- Associate Professor, Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine
Education
Degrees
- MD from Georgetown University
- MA from Georgetown University
Research
Publications
-
The Landmark Series: Melanoma and Adjuvant Therapy.
Ann Surg Oncol Volume: 32 Page(s): 3212 - 3215
05/01/2025 Authors: Lowe MC; Delman KA; Ollila DW -
Combination radiation and PD-L1 enhance tumor control by stimulating CD8+PD-1+TCF-1+T cells in the tumor-draining lymph node.
Nat Commun Volume: 16 Page(s): 3522
04/14/2025 Authors: Shen Y; Connolly E; Aiello M; Zhou C; Chappa P; Song H; Tippitak P; Clark T; Cardenas M; Prokhnevska N -
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.
Ann Surg Oncol
04/07/2025 Authors: Zager JS; Orloff M; Ferrucci PF; Choi J; Eschelman DJ; Glazer ES; Ejaz A; Howard JH; Richtig E; Ochsenreither S -
The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Oncologist Volume: 30
02/06/2025 Authors: Sebastian NT; Stokes WA; Behera M; Jiang R; Gutman DA; Huang Z; Burns A; Sukhatme V; Lowe MC; Ramalingam SS -
Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Ann Surg Oncol Volume: 31 Page(s): 8262 - 8263
11/01/2024 Authors: Zager JS; Orloff M; Ferrucci PF; Choi J; Eschelman DJ; Glazer ES; Ejaz A; Howard JH; Richtig E; Ochsenreither S -
ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study.
Ann Surg Oncol Volume: 31 Page(s): 5220 - 5221
08/01/2024 Authors: Zager JS; Orloff M; Ferrucci PF; Choi J; Eschelman DJ; Glazer ES; Ejaz A; Howard JH; Richtig E; Ochsenreither S -
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Ann Surg Oncol Volume: 31 Page(s): 5340 - 5351
08/01/2024 Authors: Zager JS; Orloff M; Ferrucci PF; Choi J; Eschelman DJ; Glazer ES; Ejaz A; Howard JH; Richtig E; Ochsenreither S -
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis.
J Immunother Cancer Volume: 12
03/26/2024 Authors: Patel JS; Woo Y; Draper A; Jansen CS; Carlisle JW; Innominato PF; Lvi FA; Dhabaan L; Master VA; Bilen MA -
Radiation and anti-PD-L1 synergize by stimulating a stem-like T cell population in the tumor-draining lymph node.
Res Sq
03/06/2024 Authors: Shen Y; Connolly E; Aiello M; Zhou C; Chappa P; Song H; Tippitak P; Clark T; Cardenas M; Prokhnevska N -
Metastasectomy in Stage IV Melanoma: How and When Should We Employ It?
Ann Surg Oncol Volume: 30 Page(s): 5312 - 5313
09/01/2023 Authors: Faries MB; Lowe M